Payment overview · 2025
General Payments
$406,226.31
633 reported records · 46 companies
Healthcare provider profile · identity verified
Peter J. Mcallister, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · FAIRFIELD, CT · NPI 1033176896
Verified facts
What the public records show
CMS Open Payments records show Peter J. Mcallister, M.D. received $406,226.31 in general payments during 2025 across 633 reported records.
ABBVIE INC. accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 59 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Gamunex-C, Qulipta, Trintellix, Ubrelvy, Vyepti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ubrelvy by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Gamunex-C by this doctor in 2024.
H. Lundbeck A S reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYEPTI as an associated drug or biological on 79 records involving 19 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vyepti by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYEPTI as an associated drug or biological on 30327 records involving 8800 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vyepti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $127,779.73 | 31.5% | 159 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96,027.87 | 23.6% | 72 | 2025 |
| H. Lundbeck A S | Unresolved — no canonical attribution shown | $56,719.88 | 14.0% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33,270.77 | 8.2% | 51 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23,511.97 | 5.8% | 46 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15,138.52 | 3.7% | 3 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $14,348.31 | 3.5% | 9 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13,785.34 | 3.4% | 11 | 2025 |
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $10,711.64 | 2.6% | 9 | 2025 |
| PFIZER INTERNATIONAL LLC | Unresolved — no canonical attribution shown | $4,800.00 | 1.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $3,165.27 | 0.8% | 26 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $2,085.29 | 0.5% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $528.02 | 0.1% | 25 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $469.27 | 0.1% | 21 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $429.73 | 0.1% | 20 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $311.54 | 0.1% | 20 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $301.79 | 0.1% | 20 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $271.53 | 0.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $261.90 | 0.1% | 11 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $228.95 | 0.1% | 12 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $193.28 | 0.1% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $164.62 | 0.0% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $163.76 | 0.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $155.96 | 0.0% | 7 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $151.45 | 0.0% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $147.12 | 0.0% | 13 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $136.81 | 0.0% | 9 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $124.67 | 0.0% | 5 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $117.98 | 0.0% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $112.98 | 0.0% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $93.66 | 0.0% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $68.77 | 0.0% | 3 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $60.55 | 0.0% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $54.45 | 0.0% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $48.87 | 0.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.41 | 0.0% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.63 | 0.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $31.64 | 0.0% | 2 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.00 | 0.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $29.10 | 0.0% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $23.77 | 0.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.98 | 0.0% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $19.81 | 0.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $18.61 | 0.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $14.78 | 0.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.33 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $156,401.01 | 60 |
| Consulting Fee | $98,252.75 | 35 |
| Honoraria | $77,599.00 | 15 |
| Travel and Lodging | $60,931.44 | 71 |
| Food and Beverage | $12,931.41 | 450 |
| Education | $110.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Eli Lilly and Company, Lilly USA, LLC | $86,622.73 | 58 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67,882.81 | 70 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | H. Lundbeck A S, Lundbeck LLC | $48,402.35 | 37 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $42,605.42 | 34 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34,195.83 | 72 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $33,223.34 | 49 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC., PFIZER INTERNATIONAL LLC | $28,106.21 | 37 | 2025 |
Source payment records
|
|||||
| EPTINEZUMAB Normalized: eptinezumab |
Drug | H. Lundbeck A S | $19,230.00 | 3 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $15,138.52 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $13,785.34 | 11 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $2,085.29 | 8 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $429.73 | 20 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $418.49 | 21 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $370.07 | 20 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $367.43 | 25 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $301.79 | 20 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $292.67 | 19 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $271.53 | 3 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $252.40 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $228.95 | 12 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $201.08 | 9 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $193.28 | 7 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $189.30 | 10 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $164.62 | 7 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $163.76 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $155.96 | 7 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $151.45 | 3 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $147.12 | 13 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $126.80 | 10 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $124.67 | 5 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $117.98 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $115.76 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $112.98 | 4 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $103.90 | 8 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $93.66 | 4 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $78.96 | 5 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $73.91 | 4 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $71.64 | 3 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $60.55 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $54.45 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $48.87 | 2 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $48.15 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $47.43 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $43.41 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $37.89 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $35.63 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $32.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $31.64 | 2 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| BREKIYA Normalized: brekiya |
Drug | Amneal Pharmaceuticals LLC | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $18.52 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 60 | exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYEPTI vyepti |
2025 | Vyepti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
60 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| H. Lundbeck A S Exact reporting entity; no affiliate inference |
2025 | VYEPTI open payments reported associated product |
CMS Open Payments — General Payments 79 supporting records · 19 recipient NPIs · example record 1251761634 |
Vyepti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | VYEPTI open payments reported associated product |
CMS Open Payments — General Payments 30327 supporting records · 8800 recipient NPIs · example record 1251760014 |
Vyepti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Sumatriptan Succinate | Sumatriptan Succinate | 92 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 14 |
| Botox | Onabotulinumtoxina | 60 | 21 |
| Gabapentin | Gabapentin | 55 | 16 |
| Alprazolam | Alprazolam | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | 12 |
| Donepezil Hcl | Donepezil Hcl | 48 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 12 |
| Clonazepam | Clonazepam | 47 | 14 |
| Qulipta | Atogepant | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 12 |
| Lorazepam | Lorazepam | 44 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 36 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 35 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 34 | suppressed |
| Prednisone | Prednisone | 32 | 15 |
| Topiramate | Topiramate | 32 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 23 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 23 | suppressed |
| Ubrelvy | Ubrogepant | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Vyepti | Eptinezumab-Jjmr | 13 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Zolmitriptan | Zolmitriptan | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Keppra | Levetiracetam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406,226.31 · 633 records | ABBVIE INC. | ACTHAR, AMYVID, APLENZIN, AUSTEDO XR, Auvelity, Azstarys, BOTOX, BREKIYA, CAPLYTA, CONTRAVE, CREXONT, Dysport, EMGALITY, EPTINEZUMAB, Fintepla, Gamunex-C, Gocovri, HYQVIA, Hizentra, INBRIJA, INFINITY, INGREZZA, JOURNAVX, KESIMPTA, KEVEYIS, KISUNLA, Leqembi, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, OXERVATE, Ocrevus, Ocrevus Zunovo, PANZYGA, PURIFIED CORTROPHIN GEL, QULIPTA, Qelbree, REXULTI, Rystiggo, Symbravo, TRINTELLIX, TRUDHESA, TYSABRI, UBRELVY, UPLIZNA, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAKIX, WATCHMAN FLX, XYWAV, Xeomin, ZAVZPRET, ZEMBRACE SYMTOUCH, ZEPOSIA, ZTLido, Zilbrysq | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error